Reports of COVID-19 vaccine, ‘Covishield’ to be available in the market in 73 days has been doing the rounds. Serum Institute of India (SII) quashed the news by clarifying that the Union government has granted permission to only manufacture the vaccine and stockpile it for future use. SII also said that the media reports are completely false and conjectural. Serum Institute of India also informed that phase-3 trials for the Oxford-AstraZeneca vaccine are still underway. SII is currently conducting phase-III clinical trials for its vaccine candidate 'Covishield' across 17 different sites in India. One of the sites includes the Post Graduate Institute of Medical Education and Research (PGIMER) in Chandigarh.